Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA5A | P35218 | 4/20 | 0.52 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA4 | P22748 | 3/20 | 0.46 |
| ▸ | CA6 | P23280 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 2/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30223423 | 1.00 | CA2 (0.52) | CA2CA1CA5ACA9CA12 | |
| SCHEMBL31262371 | 0.84 | GAA (0.44) | CA2CA1CA5ACA9CA12 | |
| SCHEMBL11150455 | 0.84 | GAA (0.44) | CA2CA1CA5ACA9CA12 | |
| SCHEMBL30659891 | 0.82 | GAA (0.43) | CA2CA1CA5ACA9CA12 | |
| SCHEMBL2634762 | 0.82 | GAA (0.43) | CA2CA1CA5ACA9CA12 | |
| SCHEMBL5559487 | 0.80 | GAA (0.41) | CA2CA1CA5ACA9CA12 | |
| SCHEMBL31628255 | 0.80 | GAA (0.41) | CA2CA1CA5ACA9CA12 | |
| SCHEMBL7049241 | 0.80 | FDPS (0.43) | CA2CA1CA5ACA9CA12 | |
| SCHEMBL5888072 | 0.80 | GAA (0.41) | CA2CA1CA5ACA9CA12 | |
| SCHEMBL30010447 | 0.80 | FDPS (0.43) | CA2CA1CA5ACA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-2137164-B1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-08-26 | — | — | EP | disclosed |
| US-8466201-B2 | Potassium ion channel modulators and uses thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-06-18 | — | — | US | disclosed |
| EP-2231594-B1 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | UNIV RAMOT (IL) | 2013-03-27 | — | — | EP | disclosed |
| EP-2137166-B1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2012-05-30 | — | — | EP | disclosed |
| US-20120065270-A1 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2012-03-15 | — | — | US | disclosed |
| EP-2231594-A2 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | Ramot at Tel-Aviv University Ltd (IL) | 2010-09-29 | — | — | EP | disclosed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2009071947-A2 | POTASSIUM ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2009-06-11 | — | — | WO | disclosed |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| WO-2007148116-A2 | TOPICAL PHARMACEUTICAL FORMULATIONS | ASTON UNIVERSITY (GB) | 2007-12-27 | — | — | WO | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| EP-0757692-A1 | METHANOL DERIVATIVES FOR TREATMENT OF RETROVIRAL INFECTIONS ESPECIALLY HIV INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995029922-A1 | METHANOL DERIVATIVES FOR TREATMENT OF RETROVIRAL INFECTIONS ESPECIALLY HIV INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-09 | — | — | WO | disclosed |
| EP-0135927-B1 | ANTIHYPERLIPIDEMIC N-BENZOYLSULFAMATES, N-BENZYLSULFAMATES AND BENZYLSULFONAMIDES, A THERAPEUTIC COMPOSITION CONTAINING SAME AND A PROCESS FOR THE PRODUCTION THEREOF | Research Corporation (US) | 1988-07-06 | — | — | EP | disclosed |
| EP-0135927-A2 | Antihyperlipidemic N-benzoylsulfamates, N-benzylsulfamates and benzylsulfonamides, a therapeutic composition containing same and a process for the production thereof | Research Corporation (US) | 1985-04-03 | — | — | EP | disclosed |
| US-4499303-A | Antihyperlipidemic N-benzoylsulfamates, N-benzylsulfamates and benzylsulfonamides | RESEARCH CORPORATION (US) | 1985-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | CA2 315/4885CA1 1399/4885CA5A 1462/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | CA2 315/4885CA1 1399/4885CA5A 1462/4885 |
| US-20120065270-A1 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | KCNN3, SCN2B, SCN1B | CA2 494/4885CA1 2362/4885CA5A 836/4885 |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | CDK5, CDK5R1, CDK4 | CA2 3085/4885CA1 4103/4885CA5A 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.